hold rate reect skeptic compani
abl attain sale growth margin target
compani beat organ revenu growth margin estim detract
thesi
thing like
strong beat healthi global market good execut easi
comp rais guid organ growth total compani
segment came ahead street estim well
prior guidanc manag attribut strong perform
broad-bas growth across end market geographi cite
doubl digit growth europ asia high-singl digit growth
america also highlight good sale execut product gain
follow sale forc restructur year ago account
beat rais guidanc organ revenu growth
ep
discoveri analyt servic da growth driven biopharma
asian food market out-performance segment driven
doubl digit growth life scienc end market ie biopharma
aca/gov particular strength biopharma appli market grew
high singl digit particularli strong instrument sale asian
diagnost dx strong doubl digit growth genom
immunodiagnost recent acquir euroimmun continu
doubl digit organ growth traction target reach plan
full year infecti diseas also strong contributor
good perform emerg market geograph dx segment
benet doubl digit growth europ low teen growth asia
high singl digit growth america
price aug usd
thing cautiou
excl lower fx higher tax benefit underli seemingli
conserv guidanc manag mind potenti
headwind around headlin name aris china/u trade
disput china revenu grow doubl digit
rais pt valuat
roll forward upward revenu growth
revis pt base june
ebitda ex option estim
slight discount peer group median
back uncertainti around compani
achiev revenu margin target
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
potenti headwind seem manag manag quantifi
product ow us china da segment
compani look potenti reloc manufactur
portion exposur could take quarter fulli migrat
instrument sale key contributor out-performance manag
highlight instrument sale key driver top line perform
qtr note capit equip sale tend lumpi
dicult forecast make dicult gain comfort
forecast ratio
period end expens expens incom incom continu ep dilut con share share sale ex amort acquir cash flowoper cash cash revenu ep incl
period end asset equival st receiv current discontinu current equip secur asset asset asset discontinu liabil short-term liabil discontinu op current debt less current long-term liabil stockhold august
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur
primari subject research pleas see recent publish compani report visit global disclosur look-up page websit http //research db com/
research/disclosures/companysearch asid within report import risk conict disclosur also found http //research db com/research/topics/equ
investor strongli encourag review inform invest
import disclosur requir regul
